Rosiglitazone Inhibits Lung Cancer Cell Growth
Author Information
Author(s): Han ShouWei, Zheng Ying, Roman Jesse
Primary Institution: Emory University School of Medicine
Hypothesis
PPARĪ³ ligands activate tuberous sclerosis complex-2 (TSC2), a tumor suppressor gene that inhibits mTOR signaling.
Conclusion
Rosiglitazone inhibits the growth of non-small cell lung carcinoma cells by activating TSC2 and suppressing mTOR signaling.
Supporting Evidence
- Rosiglitazone stimulated the phosphorylation of TSC2 at serine-1254.
- Silencing TSC2 reduced the growth inhibitory effect of rosiglitazone by fifty percent.
- Activation of TSC2 resulted in downregulation of phosphorylated p70S6K.
Takeaway
Rosiglitazone, a diabetes drug, helps stop lung cancer cells from growing by turning on a gene that slows down cell growth.
Methodology
The study used human NSCLC cell lines and various assays including Western blotting and thymidine incorporation to assess cell proliferation and signaling pathways.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website